Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Summary
Cingulate is making progress on CTx-1301 as it works toward a potential commercial launch for ADHD treatment in 2026. The company has received FDA acceptance of its NDA and now has a PDUFA date set for May 31, 2026. It also reported positive pediatric Phase 3 data and secured a commercial supply agreement with Bend Bio Sciences to support U.S. manufacturing capacity. A post-quarter financing of $6 million extended the company’s runway into the second quarter of 2026.
Classifications
industries
Fintech & Banking
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected